Isao_Teshirogi

About
 Us
 
Ø JPMA
 (Japan
 Pharmaceu0cal
 Manufacturers
 
Associa0on)
 is
 a
 voluntary
 associa0on
 comprising
 
71
 research-­‐oriented
 pharmaceu0cal
 companies.
 

 
Ø As
 a
 member
 of
 the
 IFPMA,
 JPMA
 is
 engaged
 
with
 various
 global
 issues
 in
 the
 pharmaceu0cal
 
and
 healthcare
 sector.
 

 
Ø JPMA
 con0nues
 to
 act
 globally
 for
 the
 
advancement
 of
 medical
 treatments
 for
 pa0ents
 
worldwide.
 
1

Our
 Interna/onal
 Ac/vi/es
 
“ JPMA’s
 Contribu/on
 to
 Global
 Health
 ”
 
　　　　　　　　　　　　　　　　　　　 　　 〔November
 9,
 
2012〕
 
Ø  Par/cipa/on
 in
 planning
 to
 “Global
 Health
 Innova/ve
 
Technology
 Fund（GHIT）” 　〔April
 ,
 2013〕

Holding
 the
 second
 “Asia
 Partnership
 Conference
 of
 
Pharmaceu/cal
 Associa/ons
 （APAC）”
 

 
〔April
 11-­‐12,
 2013〕
 
Ø  Mission
 :
 “To
 expedite
 the
 launch
 of
 innova/ve
 medicines
 
for
 the
 peoples
 in
 Asia”

2

Contribu/ons
 of
 the
 Pharmaceu/cal
 Industry
 
Contribu0on
 
 
to
 economic
 
 
growth
 
Creation of
drugs
(Innovation)
Profit
(Return)
R＆D
(Investment)
Contribu/on
 cycle
 
of
 Pharmaceu/cal
 
industry

Contribu0on
 
 
to
 progress
 in
 
 
science
 and
 
 
technology

Contribu0on
 to
 
create
 a
 healthy
 
 
and
 safe
 society

u Improvement
 of
 the
 level
 
 

 
 
 of
 science
 and
 technology
 
 
 
 
 

 
 
 through
 promo/on
 of
 
 
 

 
 
 advanced
 research
 
 
 
u Fostering
 specialists
 who
 
 

 
 
 
 lead
 the
 future
 advanced
 
 

 
 
 
 research
 
u Ripple
 effects
 on
 relevant
 
 

 
 
 
 industries

u Conquering
 diseases

u Extension
 of
 healthy
 
 

 
 
 
 life-­‐span

u  Stable
 and
 high
 level
 of
 tax
 
payment

u  Offers
 jobs
 for
 many
 specialists
 in
 
medicine,
 pharmaceu/cal
 
 sciences,
 
etc.
3

IFPMA
 has
 developed
 points
 for
 
　 considera/on
 on
 the
 following
 
topics
 
Use
 of
 placebo
 in
 clinical
 trials　―
 Principle
 32
 
Use
 of
 comparators
 based
 on
 differences
 in
 
standard
 of
 care
 and
 availability
 of
 medicines
 
between
 developed,
 emerging
 and
 developing
 
countries　 ―
 Principles
 32
 and
 35
 
Conduct
 of
 clinical
 trials
 in
 vulnerable
 pa/ent
 
popula/ons　―
 Principles
 9
 and
 17
 
Post-­‐study
 access
 to
 medical
 care
 　―
 Principle
 14
 
4

EOF
hLp://www.jpma.or.jp/english/